Experiences with

Sipuleucel-T

We met with my husband's onc yesterday to discuss the next move since the 3 years of Abiraraterone/prednisone has run its course. His psa numbers are now around 2.0 (up from a low of .04) and psma scan indicates that bone met volume is quite low. A recent lab biopsy didn't reveal much... The good doc

Will this immunotherapy vaccine treatment work for PC?

Here are some of the notable ones: Sipuleucel-T (Provenge): Sipuleucel-T is an autologous cellular immunotherapy approved for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

https://www.urologytimes.com/view/sipuleucel-t-boosts-survival-versus-abiraterone-or-enzalutamide-alone-in-real-world-mcrpc-analysis

D: trying something called Sipuleucel -T which I am unfamiliar with. He said that most of these options , aside from the radiation, only have a promise of a 20% chance of any major changes but they are best options. what do you guys think?

docetaxel some months after sipuleucel-T.

The manufacturing process and proposed mechanism for sipuleucel-T (3). A) The manufacturing process for sipuleucel-T is depicted.

Found online ie: Amazon *Bisphonsphanates, a group of drugs to reduce the risk of a Skeletal Related Event ; they act to bring calcium levels down, Densonumb another option to reduce the risk of SREs * The use of Vaccines such as an Apeceden vaccine and *Immunotherapies such as Provenge (Sipuleucel-T

Then, we have chemotherapy and radioactive particles, and there is immunotherapy sipuleucel-T. But there’s nothing yet that creates durable remissions. And so, the hope is that T-cell technology is where we might start to achieve that.

Among those included adjuvant radiation therapy (we lobbied and convinced a radiologist to go along with this) and Provenge (sipuleucel-T) as yet another immunotherapy option.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005. Scher HI, Fizazi K, Saad F, et al.

Palvimo and Ville Paakinaho https://erc.bioscientifica.com/view/journals/erc/aop/erc-21-0038/erc-21-0038.xml [i]Using immunotherapy in prostate cancer patients: more than -T[/i] - Author(s): Jamie Tae Wook Kwon, Richard J Bryant, and Eileen E Parkes https://erc.bioscientifica.com/view

The median OS was improved by 14.5 months with sipuleucel-T https://www.urologytimes.com/view/sipuleucel-t-boosts-survival-versus-abiraterone-or-enzalutamide-alone-in-real-world-mcrpc-analysis

Additional treatments for metastatic CRPC include taxane-based chemotherapeutic agents (docetaxel, cabazitaxel), cancer immunotherapy (sipuleucel-T) and the radiopharmaceutical radium Ra-223 dichloride (Table 2).

Im thinking provenge (sipuleucel-t) or one of the PARP inhibitors (if BRCA+) as alternatives before chemo, but seems they re indicated after having tried chemo, my understanding is that this order maybe due to high cost and not nevessarily patient outcome, so maybe if cost wasnt an issue is it worth

In a short-term phase 2 trial, Xofigo (radium 223 chloride) was combined with Provenge (sipuleucel-T) in castration-resistant patients.

Food and Drug Administration approval of the cell-based cancer immunotherapy sipuleucel-T in patients with asymptomatic CRPC with nonvisceral metastases, all other randomized trials of immunotherapy have been negative to date, and prostate cancer is believed to be a relatively immunologically "silent

While only one type of immunotherapy, Sipuleucel-T, has yielded only modest improvements in survival most other types such as viruses, PD-1 and PD-L1 inhibitors, etc. have not been very effective, because of PCa's comparatively low mutational loads, I still have hope that immunotherapy will one day be

Additional phase II and III studies incorporating radium-223 are ongoing, and are designed to evaluate combinations with enzalutamide, sipuleucel-T, and other approved and experimental agents (ClinicalTrials.gov: NCT02346526, NCT02463799, NCT02225704, NCT01929655, NCT02194842).

The phase III IMPACT trial randomized men with metastatic CRPC 2:1 to receive sipuleucel-T or placebo and found no significant difference in time to progression, but found an improved median overall survival in the sipuleucel-T group compared with the placebo group (25.8 months vs 21.7 months).[11] Survival